Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +50

Excellere Partners and GHO Capital Sell Biocare Medical to Agilent Technologies

📈 Biocare Medical has been acquired by Agilent Technologies in a deal to integrate its immunohistochemistry and diagnostics capabilities.

🤝 The transaction involves Excellere Partners and GHO Capital selling the company they have owned since 2021 to Agilent.

📈 Since gaining private equity ownership, Biocare has achieved annual double-digit revenue and profitability growth.

🔬 The company specializes in immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) solutions.

🎯 Agilent's strategy focuses on life sciences, diagnostics, and cancer diagnostics, aligning closely with Biocare's mission.

💼 Luis de Luzuriaga, CEO of Biocare, stated the acquisition is an exciting milestone to expand operational scale and accelerate innovation.

⚖️ The deal is subject to closing conditions and receipt of necessary regulatory approvals.

🏦 Jefferies is serving as exclusive financial advisor to Excellere Partners and GHO Capital for the transaction.

⚖️ Ropes & Gray LLP serves as legal advisor to Excellere Partners and GHO Capital.

💬 Excellere and GHO expressed gratitude for their partnership and praised Biocare's management team.

🌐 Agilent will leverage its global reach to unlock greater market access for Biocare's customers worldwide.

⚠️ The acquisition will help combine complementary capabilities in cancer diagnostics between both entities.

Bullish Signals
  • Biocare Medical has achieved significant growth under Excellere and GHO ownership, with annual double-digit revenue and profitability growth since 2021.
  • The company has established itself as a recognized global specialist in immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) solutions with a high-quality antibody business.
  • Agilent Technologies will provide Biocare with greater market access, enhanced customer support, and accelerated innovation through its global reach and resources.
  • The acquisition enables Biocare to expand operational scale while building on existing customer solutions and maintaining a strong focus on world-class quality and innovation.
  • Biocare has developed into a recognized leading innovator in IHC solutions that improves the diagnosis and treatment of patients, benefiting its customer base worldwide.
  • The strategic combination of complementary capabilities in cancer diagnostics between Agilent and Biocare creates a stronger position to serve life sciences and diagnostics markets.
  • Luis de Luzuriaga, CEO at Biocare, described the acquisition as an exciting milestone that aligns with the company's commitment to product quality, clinical impact, and value creation.
Risk Factors
  • The acquisition involves a sale of Biocare Medical to Agilent Technologies rather than growth via organic expansion, limiting near-term independent upside potential for Excellere Partners and GHO Capital as private equity stakeholders.
  • Transaction closing is contingent on satisfying undisclosed closing conditions and obtaining regulatory approvals from authorities, creating uncertainty around the finalization timeline.
  • The integration of Biocare into Agilent will involve operational scale-up challenges that could temporarily disrupt existing customer solutions and impact service quality.
  • Excellere Partners has only $2.3 billion of committed capital across four funds, which may limit its ability to support further independent strategic initiatives outside this transaction.
  • GHO Capital's focus on Pan-European and transatlantic internationalization contrasts with Agilent's acquisition-driven strategy, potentially leading to friction in aligning long-term investment philosophies.
Full Analysis
Excellere Partners and GHO Capital Partners LLP have announced that Biocare Medical has entered into an agreement to be acquired by Agilent Technologies. The deal marks the end of a ownership period that began in 2021, during which the company achieved annual double-digit revenue and profitability growth under its former investors' guidance. Biocare, a global leader in immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) solutions, is recognized for its high-quality antibody business and strong commercial, regulatory, and R&D capabilities with a particular expertise in cancer diagnostics. Agilent Technologies, which specializes in life sciences, diagnostics, and applied chemical markets, cited the transaction as an opportunity to expand its complementary capabilities within the cancer diagnostics sector. The acquisition will allow Biocare to grow from a position of strength while maintaining a focus on world-class quality and innovation. Excellere Partners, a Denver-based firm with $2.3 billion of committed capital across four funds, praised the Biocare management team led by CEO Luis de Luzuriaga for their success in building the company into a leading innovator. GHO Capital Partners LLP, headquartered in London, noted that Agilent represents the right partner to utilize its global reach and resources to unlock greater market access and accelerate innovation for customers worldwide. The transaction is subject to closing conditions and the receipt of transaction-related regulatory approvals. Financial advisor roles were assigned to various firms: Jefferies serves as the exclusive financial advisor and Ropes & Gray LLP as legal advisor to Excellere and GHO; Barclays acts as the financial advisor, Sullivan & Cromwell LLP as legal advisor, and Joele Frank as strategic communications advisor to Agilent. ICR Healthcare is serving as the strategic communications advisor to GHO Capital. The acquisition aligns with Biocare's commitment to product quality, clinical impact, and value creation, aiming to expand operational scale and enhance service levels for customers and partners.